Dhivy (Carbidopa/Levodopa) Patent Expiration, LOE Window & CMS Spending

Dhivy (Carbidopa/Levodopa) by Avion: FDA Orange Book LOE 2039-03-28, 10 AB generics, $1.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAvion
FDA Application & PathwayN214869 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-03-28
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$1.0M
2024 Medicare Part D Spend$979K
2024 Medicaid Spend$49K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel